Daxor (NASDAQ:DXR) Shares Down 2.4% – What’s Next?

Daxor Corporation (NASDAQ:DXR)’s share price was down 2.4% during mid-day trading on Tuesday . The company traded as low as $10.25 and last traded at $10.56. Approximately 7,426 shares traded hands during trading, a decline of 16% from the average daily volume of 8,803 shares. The stock had previously closed at $10.82.

Analysts Set New Price Targets

A number of research analysts have issued reports on DXR shares. Weiss Ratings restated a “hold (c)” rating on shares of Daxor in a research report on Friday, March 27th. Lake Street Capital started coverage on shares of Daxor in a research report on Wednesday, February 11th. They set a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Daxor Price Performance

The business’s 50-day moving average is $10.26 and its two-hundred day moving average is $11.92.

Daxor (NASDAQ:DXR) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.10) earnings per share for the quarter.

Institutional Trading of Daxor

A number of hedge funds have recently modified their holdings of DXR. Osaic Holdings Inc. acquired a new stake in shares of Daxor in the 2nd quarter valued at approximately $86,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Daxor in the 4th quarter valued at approximately $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Daxor in the 1st quarter valued at approximately $245,000. Crescent Grove Advisors LLC acquired a new stake in shares of Daxor in the 1st quarter valued at approximately $104,000. Finally, Aristides Capital LLC acquired a new stake in shares of Daxor in the 1st quarter valued at approximately $403,000. 1.34% of the stock is currently owned by institutional investors and hedge funds.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.